Reduced firing rates of pyramidal cells in the frontal cortex of APP/PS1 can be restored by acute treatment with levetiracetam
dc.contributor.author | Klee, Jan L. | |
dc.contributor.author | Kiliaan, Amanda J. | |
dc.contributor.author | Lipponen, Arto | |
dc.contributor.author | Battaglia, Francesco P. | |
dc.date.accessioned | 2020-09-21T14:15:48Z | |
dc.date.available | 2020-09-21T14:15:48Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Klee, J. L., Kiliaan, A. J., Lipponen, A., & Battaglia, F. P. (2020). Reduced firing rates of pyramidal cells in the frontal cortex of APP/PS1 can be restored by acute treatment with levetiracetam. <i>Neurobiology of Aging</i>, <i>96</i>, 79-86. <a href="https://doi.org/10.1016/j.neurobiolaging.2020.08.013" target="_blank">https://doi.org/10.1016/j.neurobiolaging.2020.08.013</a> | |
dc.identifier.other | CONVID_41867727 | |
dc.identifier.uri | https://jyx.jyu.fi/handle/123456789/71829 | |
dc.description.abstract | In recent years aberrant neural oscillations in various cortical areas have emerged as a common physiological hallmark across mouse models of amyloid pathology and patients with Alzheimer's disease. However, much less is known about the underlying effect of amyloid pathology on single cell activity. Here, we used high density silicon probe recordings from frontal cortex area of 9 months old APP/PS1 mice to show that Local Field Potential (LFP) power in the theta and beta band is increased in transgenic animals, while single cell firing rates, specifically of putative pyramidal cells, are significantly reduced. At the same time, these sparsely firing pyramidal cells phase-lock their spiking activity more strongly to the ongoing theta and beta rhythms. Furthermore, we demonstrated that the anti-epileptic drug, levetiracetam, counteracts these effects by increasing pyramidal cell firing rates in APP/PS1 mice and uncoupling pyramidal cells and interneurons. Overall, our results highlight reduced firing rates of cortical pyramidal cells as a pathophysiological phenotype in APP/PS1 mice and indicate a potentially beneficial effect of acute levetiracetam treatment. | en |
dc.format.mimetype | application/pdf | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartofseries | Neurobiology of Aging | |
dc.rights | CC BY-NC-ND 4.0 | |
dc.subject.other | amyloid | |
dc.subject.other | local field potential (LFP) | |
dc.subject.other | single cell | |
dc.subject.other | firing rate | |
dc.subject.other | mouse model | |
dc.subject.other | Alzheimer’s disease | |
dc.title | Reduced firing rates of pyramidal cells in the frontal cortex of APP/PS1 can be restored by acute treatment with levetiracetam | |
dc.type | article | |
dc.identifier.urn | URN:NBN:fi:jyu-202009215912 | |
dc.contributor.laitos | Psykologian laitos | fi |
dc.contributor.laitos | Department of Psychology | en |
dc.contributor.oppiaine | Psykologia | fi |
dc.contributor.oppiaine | Psychology | en |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | |
dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | |
dc.description.reviewstatus | peerReviewed | |
dc.format.pagerange | 79-86 | |
dc.relation.issn | 0197-4580 | |
dc.relation.volume | 96 | |
dc.type.version | acceptedVersion | |
dc.rights.copyright | © 2020 Elsevier | |
dc.rights.accesslevel | openAccess | fi |
dc.subject.yso | Alzheimerin tauti | |
dc.subject.yso | amyloidoosi | |
dc.subject.yso | hermosolut | |
dc.subject.yso | patofysiologia | |
dc.format.content | fulltext | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p8412 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p5248 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p18309 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p11545 | |
dc.rights.url | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.relation.doi | 10.1016/j.neurobiolaging.2020.08.013 | |
jyx.fundinginformation | The study was supported by the Säätiöiden post doc -pooli (The Finnish Cultural Foundation) to Dr. Arto Lipponen. Silicon probes were manufactured by IMEC (Leuven, Belgium) with funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement nr. 600925 (NeuroSeeker). | |
dc.type.okm | A1 |